Prostate Cancer Managed with Active Surveillance: Role of Anatomic MR Imaging and MR Spectroscopic Imaging

被引:101
|
作者
Fradet, Vincent [2 ]
Kurhanewicz, John [1 ]
Cowan, Janet E. [2 ]
Karl, Alexander [2 ]
Coakley, Fergus V. [2 ]
Shinohara, Katsuto [2 ]
Carroll, Peter R. [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Urol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
基金
美国国家卫生研究院;
关键词
ENDORECTAL MR; INCREMENTAL VALUE; TUMOR; MEN; PREDICTION; ANTIGEN; LOCALIZATION; SUPPRESSION; BIOPSY; MARKER;
D O I
10.1148/radiol.10091147
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine the role that magnetic resonance (MR) imaging and MR spectroscopic imaging findings obtained at the time of diagnosis play in the progression of disease in patients whose prostate cancer is being managed with active surveillance and to compare the role of these findings with the role of transrectal ultrasonography (US) findings. Materials and Methods: The institutional review board approved this HIPAA-compliant retrospective study, and informed consent was obtained from all patients whose records were to be entered into the research database. All patients who had prostate cancer managed with active surveillance and who had undergone both MR imaging and MR spectroscopic imaging of the prostate and transrectal US at time of diagnosis were identified. Two urologists blinded to the clinical outcome in these patients independently reviewed and dichotomized the MR imaging report and the MR spectroscopic imaging report as normal or suggestive of malignancy. One experienced urologist performed all US examinations that were then dichotomized similarly. Uni- and multivariate (with use of standard clinical variables) Cox models were fitted to assess time to cancer progression, defined as Gleason score upgrading, prostate-specific antigen velocity of more than 0.75 (mu g . L-1)/y, or initiation of treatment more than 6 months after diagnosis. Results: The final cohort included 114 patients with a median follow-up of 59 months. Patients with a lesion that was suggestive of cancer at MR imaging had a greater risk of the Gleason score being upgraded at subsequent biopsy (hazard ratio, 4.0; 95% confidence interval: 1.1, 14.9) than did patients without such a lesion. Neither MR spectroscopic imaging nor transrectal US could be used to predict cancer progression. Conclusion: Abnormal prostate MR imaging results suggestive of cancer may confer an increased risk of Gleason score upgrade at subsequent biopsy. Although expensive, prostate MR imaging may help in counseling potential candidates about active surveillance. (C) RSNA, 2010
引用
收藏
页码:176 / 183
页数:8
相关论文
共 50 条
  • [41] MR imaging of the prostate
    Asbach, P.
    Haas, M.
    Hamm, B.
    [J]. RADIOLOGE, 2015, 55 (12): : 1088 - 1095
  • [42] MR Imaging of the Prostate
    Yacoub, Joseph H.
    Oto, Aytekin
    Miller, Frank H.
    [J]. RADIOLOGIC CLINICS OF NORTH AMERICA, 2014, 52 (04) : 811 - +
  • [43] MR imaging of the prostate
    Hricak H.
    [J]. Cancer Imaging, 2002, 2 (2) : 81 - 83
  • [44] Role of dynamic contrast enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer
    Sciarra, Alessandro
    Panebianco, Valeria
    Salciccia, Stefano
    Gomez, Ana Maria Autran
    Gentilucci, Alessandro
    Gentile, Vincenzo
    [J]. JOURNAL OF UROLOGY, 2008, 179 (04): : 642 - 642
  • [45] Role of Prostate MR Imaging in Radiation Oncology
    Menard, Cynthia
    Paulson, Eric
    Nyholm, Tufve
    McLaughlin, Patrick
    Liney, Gary
    Dirix, Piet
    van der Heide, Uulke A.
    [J]. RADIOLOGIC CLINICS OF NORTH AMERICA, 2018, 56 (02) : 319 - +
  • [46] Detection of prostate cancer with MR spectroscopic imaging: An expanded paradigm incorporating Polyamines
    Shukla-Dave, Amita
    Hricak, Hedvig
    Moskowitz, Chaya
    Ishill, Nicole
    Akin, Oguz
    Kuroiwa, Kentaro
    Spector, Jessica
    Kumar, Mahesh
    Reuter, Victor E.
    Koutcher, Jason A.
    Zakian, Kristen L.
    [J]. RADIOLOGY, 2007, 245 (02) : 499 - 506
  • [47] MRI AND 1H - MR SPECTROSCOPIC IMAGING IN THE EVALUATION OF PROSTATE CANCER
    Manenti, Guglielmo
    Francioni, Piero
    Mancino, Stefano
    Squillaci, Ettore
    Simonetti, Giovanni
    [J]. ANTICANCER RESEARCH, 2004, 24 (5D) : 3558 - 3558
  • [48] Pretreatment evaluation of prostate cancer:: Role of MR imaging and 1H MR spectroscopy
    Claus, FG
    Hricak, H
    Hattery, RR
    [J]. RADIOGRAPHICS, 2004, 24 : S167 - S180
  • [49] MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer (vol 78, S103, 2005)
    Zakian, K. L.
    Sircar, K.
    Hricak, H.
    Chen, H. N.
    Shukla-Dave, A.
    Eberhardt, S.
    [J]. BRITISH JOURNAL OF RADIOLOGY, 2016, 89 (1061):
  • [50] Combined quantitative dynamic contrast-enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer
    van Dorsten, FA
    van der Graaf, M
    Engelbrecht, MRW
    van Leenders, GJLH
    Verhofstad, A
    Rijpkema, M
    de la Rosette, JJMCH
    Barentsz, JO
    Heerschap, A
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2004, 20 (02) : 279 - 287